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Case Report
Progression of Prostate Cancer Despite an Extremely Low Serum 
Level of Prostate-Specific Antigen
Dong Kil Lee, Jeong Hyun Park, Jae Han Kim, Seung Joon Lee, Moon Ki Jo, Myung Cheol Gil, 
Kang Hyon Song, Jong Wook Park
Department of Urology, Korea Cancer Center Hospital, Seoul, Korea
A 61-year-old man who had been diagnosed with prostate cancer 9 years ago and had 
been treated with pelvic irradiation and intermittent androgen deprivation therapy 
visited the emergency room because of back pain and weakness in both legs. Spine mag-
netic resonance imaging showed a lumbar epidural mass and spine metastasis. The 
whole-body workup revealed multiple metastases to the lymph nodes, bone, liver, and 
lung. The serum prostate-specific antigen was 0.02 ng/ml. He underwent laminectomy, 
posterior fixation, and epidural mass excision, and metastatic adenocarcinoma from 
the prostate was diagnosed. The patient underwent 1 cycle of docetaxel-based 
chemotherapy. More chemotherapy could not be done because of his general weakness. 
The patient died one month later of multiple organ failure.
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The serum prostate-specific antigen (PSA) level has been 
used since the 1980s to monitor patients after treatment 
for prostate cancer. The kinetics of PSA after the treatment 
of prostate cancer make it a sensitive marker for the activ-
ity and status of this disease. Many studies have suggested 
that PSA may be the most valuable factor for predicting the 
activity and volume of prostate cancer [1]. 
　Almost all patients with metastatic prostate cancer pres-
ent with a high serum PSA level. However, progression of 
prostate cancer can sometimes occur despite a low serum 
PSA level. Those patients with metastatic prostate cancer 
and a low serum level of PSA account for less than 1% of 
all patients with metastatic prostate cancer [2]. There have 
been only a few reports about these patients. In these cases, 
androgen deprivation therapy (ADT) is relatively in-
effective, and the prostate cancer progresses very quickly 
[3]. Therefore, the prognosis is generally poor compared 
with the usual metastatic prostate cancer. Here we report 
the case of a patient who had multiple sites of metastatic 
prostate cancer and a low serum level of PSA during inter-
mittent ADT. We also review the related literature. 
CASE REPORT
A 52-year-old male patient visited our institute for lower 
urinary tract symptoms on 18, September 2000. His initial 
PSA level was 21.6 ng/ml. A firm, nontender prostate with 
enlarged lobes was found on the digital rectal examination. 
Prostate biopsy showed the tumor to be an adenocarcinoma 
with a Gleason score of 8 (4＋4) (Fig. 1A). Prostate magnetic 
resonance imaging (MRI) and a whole-body bone scan were 
subsequently performed and the patient was diagnosed as 
having a clinical stage T1cN0M0 prostate adenocarcinoma. 
　The patient and his family desired a nonsurgical treat-
ment, and we recommended radiation therapy with ADT. 
He underwent 64.8 Gy of whole-pelvis irradiation for pros-
tate cancer. He underwent adjuvant ADT for the first 3 
years and then he underwent intermittent ADT for the next 
5 years.
　His serum PSA level was regularly checked. His highest 
PSA level was 3.05 ng/ml and the nadir PSA was 0.02 ng/ml. 
The PSA level dropped to 0.02 ng/ml at 7 years after radia-
tion therapy and this level persisted (Fig. 2). We performed 
abdomen and pelvis computed tomography (CT) and 
whole-body bone scanning 4 and 7 years ago and found no 
evidence of recurrence. 
　Nine years after the radiotherapy, he presented with 
lower back pain and weakness in both legs. Spine MRI re-
vealed a lumbar epidural mass and spine metastasis with 
a compression fracture. The whole-body bone scan, posi-Korean J Urol 2010;51:358-361
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FIG. 1. (A) Histology of prostate adenocarcinoma of Gleason's grade 8 (4＋4) 9 years previously. Irregular sizes of glands and fusioned 
glands are shown (H&E, x400). (B) Histology of epidural metastatic adenocarcinoma of Gleason's grade 10 (5＋5). No glandular 
differentiation and focal necrosis are shown (H&E, x400).
FIG. 2. Clinical course of the patient. The serum prostate-specific 
antigen (PSA) level declined after irradiation and androgen de-
privation therapy (ADT). The highest PSA was 3.05 ng/ml. Since 
2007, the serum PSA level was 0.02 ng/ml. 
tron emission tomography, and abdomen, pelvis, and chest 
CT revealed multiple metastases to the lymph nodes, bone, 
liver, and lung (Fig. 3). The patient’s serum PSA level was 
only 0.02 ng/ml. He underwent laminectomy, posterior fix-
ation, and epidural mass excision; he was diagnosed with 
metastatic adenocarcinoma and he had a Gleason score of 
10 (5＋5) (Fig. 1B). The malignant cells were negative for 
synaptophysin, chromogranin A, and CD56. Therefore, im-
munohistochemical studies were not consistent with a di-
agnosis of neuroendocrine or small cell prostate cancer. He 
was examined for other serum tumor markers. The values 
of carcinoembryonic antigen (CEA), α-fetoprotein (αFP), 
and β-human chorionic gonadotropin (β-HCG) were all 
within the normal ranges. However, CA 19-9 was 73.47 
U/ml and CA 15-3 was 25.98 U/ml, and these values were 
slightly higher than the normal range. He was also exam-
ined via duodenoscopy and colonoscopy, which showed no 
evidence of malignancy. 
　He received 1 cycle of docetaxel-based chemotherapy. 
After chemotherapy, his general weakness was aggravated, 
so no more chemotherapy could be done. He died one month 
later of multiple organ failure. 
DISCUSSION
ADT as a treatment for patients with prostate cancer was 
started 60 years ago. Monitoring the level of PSA has cre-
ated a dramatic shift in the population of patients for whom 
androgen ablation is initiated. This has resulted in several 
changing concepts of treatment. Patients with recurrent 
prostate cancer after the failure of local therapy are now 
being newly diagnosed with recurrent disease on the basis 
of a rising PSA level. 
　The PSA level is the most valuable tool for monitoring 
disease status and the treatment response, especially in 
patients with advanced metastatic prostate cancer, as 
shown in many studies [1,4,5]. However, the progression 
of prostate cancer can sometimes occur in the presence of 
an undetectable or low serum PSA level. Yamamoto et al 
reported on 8 patients with clinically assessed M1 prostate 
cancer, and their serum PSA levels were less than 10 ng/ml. 
Most of them had poorly differentiated or undifferentiated 
tumors and they had a poor prognosis compared with the 
usual M1 prostate cancer. Yamamoto et al reported that 
ADT was ineffective in these cases and therefore that sys-
temic chemotherapy and irradiation therapy should be rec-
ommended as the initial therapy [3]. 
　Sella et al reported on 18 patients with clinically pro-
gressive androgen-independent prostate cancer and low 
PSA levels. Each patient demonstrated elevation of at least 
one tumor marker, such as CEA, CA 19-9, CA 15-3, and CA 
125. Neuroendocrine immunoreactivity was detected in all 
specimens. They reported that progressive androgen-in-Korean J Urol 2010;51:358-361
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FIG. 3. Multiple metastatic prostate cancer in the patient. (A) Abdomen and pelvic computed tomography (CT) showing multiple 
hepatic metastases. (B) Chest CT showing a small nodule of pulmonary metastasis. (C) Positron emission tomography (PET) showing 
multiple hepatic and aortocaval, paraaortic, and both common iliac lymph node metastases. (D) Whole-body bone scan showing an 
active bony lesion in L4.
dependent prostate cancer and a low serum PSA level was 
characterized by visceral metastasis, a high proportion of 
lytic bone disease, sensitivity to cisplatin-based chemo-
therapy, and the histological features of small cell or poorly 
differentiated prostate cancer [6]. Nishio et al also reported 
that serum CEA, CA 19-9, and CA 15-3 were elevated in 
patients with metastatic prostate cancer who had normal 
serum PSA levels [7]. 
　Compared with the previous reports of metastatic pros-
tate cancer patients with low PSA levels, our case pre-
sented with a high-grade Gleason score, a low PSA level of 
less than 0.1 ng/ml, visceral metastasis, and elevated levels 
of the tumor markers CA 19-9 and CA 15-3. However, there 
was no neuroendocrine component. 
　Given the biological heterogeneity of prostate cancer and 
its multifocality, it is possible that tumors with a higher 
Gleason grade have a greater chance for occurrence of a clo-
nal shift in the original tumor that may express the fea-
tures of other prostate cancers, including biological ag-
gressiveness, and that such tumors may be associated with 
a lack of PSA production. The phenomenon of prostate can-
cer progression without concomitant PSA elevation may be 
explained by the proliferation of cell lines that either can-
not produce PSA or are poorly differentiated prostate can-
cer cells that have lost their ability to express PSA. 
Magklara et al reported that both PSA and human kallik-
rein 2 are expressed more in noncancerous prostatic tissue 
than in cancerous prostatic tissue [8]. 
　Only limited data are available to analyze the reason for 
recurrent prostate cancer with a low serum PSA. The lim-
ited reported experience suggests that the prognosis of pa-
tients with recurrence and without detectable serum PSA 
is variable. Oefelein et al reported that patients who had 
prostate cancer progression with undetectable serum PSA 
levels after radical prostatectomy had rapid progression 
[9]. Korean J Urol 2010;51:358-361
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　In conclusion, prostate cancer may progress despite low 
serum PSA levels. Although this is an uncommon clinical 
scenario, patients with a high-grade Gleason score and un-
differentiated tumors can progress to this event. A com-
plete physical evaluation, including a digital rectal exami-
nation, imaging studies, and measurement of the serum 
PSA level, may be helpful in the follow-up of patients with 
these prostate cancers. 
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